Joinn Laboratories and Biomere merged to form a new premier, global nonclinical contract research organization (CRO). The Joinn-Biomere merger creates a new and expanded North American business subsidiary greatly enhancing our global scale and international footprint, while complementing and expanding on our scientific portfolio.
Our U.S. bi-coastal locations offer an extensive portfolio of preclinical research services from in vitro analyses, early discovery and proof-of-concept to discovery toxicology. Nonclinical capabilities include: pharmacokinetics, lead compound screening, proof of concept, efficacy assessment, pharmacology, mechanism of action, and early lead optimization. Biomere also provides supportive colony maintenance and backup colony support.
A pioneer in commercial GLP services, Joinn Laboratories is a leading CRO in China with facilities located in Suzhou, Beijing, Wuzhou and Chongqing. With locations on the east and west coast and China, we are ideally suited to support our clients’ needs.